JPRN-jRCT2080222474已完成3 期
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 705
研究概览
简要总结
Primary Outcome Results; Refer to attached file on this record. In patients with newly diagnosed multiple myeloma (NDMM), the safety results of oral ixazomib versus placebo when added to lenalidomide and dexamethasone (LenDex) as their standard therapy are consistent with those in the original CSR. The cumulative safety profile of ixazomib + LenDex in patients with NDMM in global Study C16014 further supports the established tolerability of ixazomib.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Male or female participants 18 years or older diagnosed with Multiple Myeloma according to standard criteria who have not received prior treatment
- •- Participants for whom lenalidomide and dexamethasone treatment is appropriate and who are not eligible for high-dose therapy followed by stem-cell transplantation (HDT-SCT) for 1 or more of the following reasons:
- •i. Participant is 65 years of age or older
- •ii.Participant is less than 65 years of age but has significant comorbid condition(s) that are, in the opinion of the investigator, likely to have a negative impact on tolerability of HDT-SCT
- •- Measurable disease as specified in study protocol
- •- Eastern Cooperative Oncology Group (ECOG)performance status of 0 to 2
- •- Meet the clinical laboratories criteria as specified in the protocol
- •- Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to practice true abstinence, and must also agree to ongoing pregnancy testing; must also adhere to the guidelines of the lenalidomide pregnancy prevention program
- •- Male participants who agree to practice effective barrier contraception or agree to practice true abstinence AND must adhere to the guidelines of the lenalidomide pregnancy prevention program
- •- Suitable venous access for the study-required blood sampling
- •- Must be able to take concurrent aspirin 70mg to 325 mg daily (or enoxaparin if aspirin allergic)
- •- Voluntary written consent
- •- Participant is willing and able to adhere to the study visit schedule and other protocol requirements
排除标准
- •- Prior treatment for multiple myeloma with either standard of care treatment or investigational regimen
- •- Diagnosed and treated for another malignancy within 5 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
- •- Inability or unwillingness to receive antithrombotic therapy
- •- Female patients who are breast feeding or pregnant
- •- Major surgery or radiotherapy within 14 days before randomization
- •- Infection requiring intravenous antibiotics within 14 days before the first dose of study drug
- •- Central nervous system involvement
- •- Diagnosis of Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome
- •- Evidence of current uncontrolled cardiovascular conditions
- •- Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before randomization in the study
- •- Active hepatitis B or C virus infection, or known human immunodeficiency virus(HIV) positive
- •- Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens (eg, peripheral neuropathy that is Grade 1 with pain or Grade 2 or higher of any cause)
- •- Serious medical or illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol
- •- Known allergy to any of the study medications
- •- Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment
- •- Treatment with any investigational products within 60 days before the first dose of the study drug regimen
研究者
相似试验
进行中（未招募）
3 期
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.Chronic Graft Versus Host DiseaseNCT06143891Sanofi260
已完成
1 期
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerEsophagogastric Junction AdenocarcinomaGastric CancerEsophageal CancerNCT00719550Amgen130
已完成
3 期
SVT-15652 Otic Solution for the Treatment of OtomycosisOtomycosisNCT03686384Salvat217
已完成
3 期
SVT-15652 Otic Solution for the Treatment of Otomycosis.OtomycosisNCT03686397Salvat194
终止
3 期
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's DiseaseAlzheimer DiseaseNCT00912288Pfizer86